Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Rusfertide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda touts 6 pipeline assets with big sales potential
    Takeda touts 6 pipeline assets with big sales potential

    16 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jpm25-takeda-spotlights-6-later-stage-assets-could-subvert-entyvio-pressures-20b-collective

    FIERCE PHARMA
    16 Jan 2025
    Share Share
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress

    14 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=877298&lang=en

    ACCESSWIRE
    14 Jun 2024
    Share Share
    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024

    14 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/863148/protagonist-therapeutics-announces-oral-presentation-on-long-term-follow-up-of-rusfertide-phase-2-revive-study-open-label-extension-at-the-european-hematology-association-2024-congress

    ACCESSWIRE
    14 May 2024
    Share Share
    Protagonist Announces Closing of Worldwide Rusfertide License
    Protagonist Announces Closing of Worldwide Rusfertide License

    18 Mar 2024

    // ACCESSWIRE

    https://www.accesswire.com/843636/protagonist-therapeutics-announces-closing-of-worldwide-rusfertide-license-and-collaboration-agreement-with-takeda

    ACCESSWIRE
    18 Mar 2024
    Share Share
    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide

    21 Feb 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=835611&lang=en

    ACCESSWIRE
    21 Feb 2024
    Share Share
    Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
    Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide

    31 Jan 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=829846&lang=en

    ACCESSWIRE
    31 Jan 2024
    Share Share